Identification of accrual barriers onto breast cancer prevention clinical trials

• Published in: Cancer 2010-08, Vol.116 (15), p.3569-3576
• Main Authors: Houlihan, Robert H., Kennedy, Michael H., Kulesher, Robert R., Lemon, Stephenie C., Wickerham, D. Lawrence, Hsieh, Chung‐Cheng, Altieri, Dario C.
• Format: Article
• Language: English
• Subjects: accrual barriers; breast cancer; cancer prevention; clinical trials; clinical trials accrual; trial barriers
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/cncr.25230

BACKGROUND: The purpose of this study was to examine factors influencing a woman's decision to participate in a breast cancer prevention clinical trial. Nine healthcare organizations in Massachusetts cooperated in the present project. METHODS: The authors performed a case‐control study to compare responses between the study group (Study of Tamoxifen and Raloxifene [STAR] trial eligible, but not enrolled) and the control group (STAR trial participants) on 12 factors previously identified as barriers to accrual for clinical trials. Eight hypotheses were tested using multiple logistic regression to estimate the strength of the association for each factor on the dependent variable (study participation). RESULTS: The study samples were similar to the general population of eligible breast cancer prevention clinical trial subjects in the counties where the participating organizations were located, the state of Massachusetts, and nationally published STAR trial data. Results of a mailed questionnaire showed that when adjusting for subject demographics, and in the presence of other questions, 4 factors significantly influenced a woman's decision to enroll onto a breast cancer prevention clinical trial more than other eligible subjects: 1) clinician expertise and qualifications (P = .012; odds ratio [OR], 4.903; 95% confidence interval [CI], 1.41‐17.04); 2) personal desire to participate (P = .033; OR, 3.16; 95% CI, 1.10‐9.06); 3) perceived value of the trial (P = .020; OR, 2.92; 95% CI, 1.18‐7.21); and 4) level of trial inconvenience (P = .002; OR, 0.10; 95% CI, 0.02‐0.44). CONCLUSIONS: Addressing these issues in the relationship between patients and clinicians should improve accrual to breast cancer prevention clinical trials. Cancer 2010. © 2010 American Cancer Society. A case‐control study of 242 women in Massachusetts compared responses between the study group (Study of Tamoxifen and Raloxifene [STAR] trial eligible, but not enrolled) and the control group (STAR trial participants). Results of the study suggest that addressing the issues identified in this study, in the relationship between patients and clinicians, should improve accrual to breast cancer prevention clinical trials.